EUVIMEDEUVIMED entdecken
Crossref

Pegzilarginase (Loargys)

CDA-AMC

Canadian Journal of Health Technologies · 23.10.2026 · 6 (10)

DOI: 10.51731/cjht.2026.1551 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Canadian Journal of Health Technologies, online erschienen am 23.10.2026. Verfasst von CDA-AMC.

AbstractBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Reimbursement reviews are comprehensive assessments of the clinical effectiveness and cost-effectiveness, as well as patient and clinician perspectives, of a drug or drug class. The assessments inform nonbinding recommendations that help guide the reimbursement decisions of Canada’s federal, provincial, and territorial governments, with the exception of Quebec. This review assesses pegzilarginase (Loargys), 5 mg/mL, for IV infusion after dilution or subcutaneous injection. Indication: Treatment of hyperargininemia in adults and pediatric patients aged 2 years and older with arginase 1 deficiency, in conjunction with dietary protein restriction.

Zitieren

APA

CDA-AMC (2026). Pegzilarginase (Loargys). Canadian Journal of Health Technologies, 6(10). https://doi.org/10.51731/cjht.2026.1551

Vancouver

CDA-AMC. Pegzilarginase (Loargys). Canadian Journal of Health Technologies. 2026;6(10). doi:10.51731/cjht.2026.1551

BibTeX
@article{CDAAMC2026,
  author = {CDA-AMC},
  title = {Pegzilarginase (Loargys)},
  journal = {Canadian Journal of Health Technologies},
  year = {2026},
  volume = {6},
  number = {10},
  doi = {10.51731/cjht.2026.1551}
}
Kostenlos starten →